Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response

被引：0
|
作者：
Mai, Nicholas
Safonov, Anton
Marra, Antonio
Chen, Yuan
Chandarlapaty, Sarat
Razavi, Pedram
Plitas, George
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] European Inst Oncol IRCCS, Div Early Drug Dev, Milan, Italy
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1078
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
    Klempner, Samuel J.
    Fabrizio, David
    Bane, Shalmali
    Reinhart, Marcia
    Peoples, Tim
    Ali, Siraj M.
    Sokol, Ethan S.
    Frampton, Garrett
    Schrock, Alexa B.
    Anhorn, Rachel
    Reddy, Prasanth
    ONCOLOGIST, 2020, 25 (01): : E147 - E159
  • [42] Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
    Vryza, Paraskevi
    Fischer, Timo
    Mistakidi, Elena
    Zaravinos, Apostolos
    TRANSLATIONAL ONCOLOGY, 2023, 38
  • [43] Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer
    Liddell, Savannah S.
    Chakrabarti, Sakti
    Wintheiser, Grant A.
    Zemla, Tyler J.
    Shi, Qian
    Tella, Sri Harsha
    Jin, Zhaohui
    Wookey, Vanessa B.
    Hassan, Hind
    Tran, Nguyen H.
    Borad, Mitesh J.
    Mahipal, Amit
    JCO PRECISION ONCOLOGY, 2022, 6
  • [44] INTEGRATING TUMOR MUTATIONAL BURDEN AND TRANSCRIPTOME EXPRESSION INTO PREDICTION OF IMMUNE CHECKPOINT INHIBITOR RESPONSE AND PROGNOSIS OF PATIENTS WITH COLON CANCER
    Liang, L.
    Jiang, W.
    Zheng, Y.
    Liu, T.
    Shen, X.
    Chen, Y.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 73 (02):
  • [45] Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
    Thomas, Alexandra
    Routh, Eric D.
    Pullikuth, Ashok
    Jin, Guangxu
    Su, Jing
    Chou, Jeff W.
    Hoadley, Katherine A.
    Print, Cristin
    Knowlton, Nick
    Black, Michael A.
    Demaria, Sandra
    Wang, Ena
    Bedognetti, Davide
    Jones, Wendell D.
    Mehta, Gaurav A.
    Gatza, Michael L.
    Perou, Charles M.
    Page, David B.
    Triozzi, Pierre
    Miller, Lance D.
    ONCOIMMUNOLOGY, 2018, 7 (10):
  • [46] Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports
    Moog, Sophie
    Lamartina, Livia
    Bani, Mohamed-Amine
    Al Ghuzlan, Abir
    Friboulet, Luc
    Italiano, Antoine
    Lacroix, Ludovic
    Vinay, Sophie Postel
    Tselikas, Lambros
    Deschamps, Frederic
    Bonnet, Baptiste
    Pani, Fabiana
    Baudin, Eric
    Hadoux, Julien
    THYROID, 2023, : 1368 - 1373
  • [47] Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI)
    Chumsri, S.
    Sammons, S.
    Alder, L.
    Sokol, E.
    Danziger, N. A.
    Raskina, K.
    Schrock, A. B.
    Venstrom, J.
    Snow, T.
    Castellanos, E.
    Ochuonyo, E.
    Snider, J.
    Mcgregor, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S462 - S463
  • [48] Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA
    Barnett, Reagan
    Lanka, Sree M.
    Clemens, Keelia M.
    Kiedrowski, Lesli Ann
    Babiker, Hani M.
    Bryce, Alan Haruo
    Meyer, Haley M.
    Choi, Yujin
    Garje, Rohan
    Gao, Xin
    Chang, Richard Y.
    Jang, Albert
    Gulhati, Pat
    Bilen, Mehmet Asim
    Barata, Pedro C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience
    Tracy L. Rose
    William H. Weir
    Gregory M. Mayhew
    Yoichiro Shibata
    Patrick Eulitt
    Joshua M. Uronis
    Mi Zhou
    Matthew Nielsen
    Angela B. Smith
    Michael Woods
    Michele C. Hayward
    Ashley H. Salazar
    Matthew I. Milowsky
    Sara E. Wobker
    Katrina McGinty
    Michael V. Millburn
    Joel R. Eisner
    William Y. Kim
    British Journal of Cancer, 2022, 126 : 1237 - 1237
  • [50] Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers
    Barnett, Reagan M.
    Jang, Albert
    Lanka, Sree
    Fu, Pingfu
    Bucheit, Leslie A.
    Babiker, Hani
    Bryce, Alan
    Meyer, Haley M.
    Choi, Yujin
    Moore, Casey
    Garje, Rohan
    Gao, Xin
    Kim, Dae Won
    Chang, Richard Y.
    Gulhati, Pat
    Ramaker, Ryne
    Bansal, Rani
    Zhang, Tian
    Oliver Sartor, A.
    Armstrong, Andrew J.
    Bilen, Mehmet A.
    Barata, Pedro
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
12345